ACHL NASDAQ
Achilles Therapeutics plc
1W: +2.8%
1M: +7.2%
3M: +53.4%
1Y: +14.7%
3Y: -52.9%
$1.48
Last traded 2025-03-24 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$5M
-28.3% ▼
Operating Income
-$75M
+4.0% ▲
Net Income
-$70M
+2.1% ▲
EPS (Diluted)
$-1.74
+4.4% ▲
EBITDA
-$70M
-4.6% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $303K | $778K | $3M | $4M | $5M |
| Gross Profit | -$303K | -$778K | -$3M | -$4M | -$5M |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $9M | $23M | $42M | $57M | $68M |
| SG&A Expenses | $5M | $11M | $22M | $21M | $12M |
| Operating Expenses | $14M | $34M | $64M | $78M | $75M |
| Operating Income | -$14M | -$34M | -$64M | -$78M | -$75M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$14M | -$33M | -$61M | -$71M | -$69M |
| Tax Expense | $130K | $3K | $37K | $111K | $491K |
| Net Income | -$14M | -$33M | -$61M | -$71M | -$70M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-20.48 | $-0.82 | $-2.13 | $-1.82 | $-1.74 |
| EBITDA | -$13M | -$33M | -$61M | -$67M | -$70M |
| Shares Outstanding | 683085 | 41M | 29M | 39M | 40M |